Long Term Follow up Study of Predictive Markers in GHD and TS Children

NCT00699855 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2014-02-19

No results posted yet for this study

Summary

Primary objective is to assess the relationship between changes from serum biomarkers observed after 1 month of Saizen® therapy and change in height, weight after up to 5 years of treatment with Growth Hormone in children with Growth Hormone Deficiency (GHD) and Turner Syndrome (TS).

Conditions

  • Growth Hormon Deficiency
  • Turner Syndrome in Pre-pubertal Children

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Gilles Della Corte · Merck Serono S.A., Geneva

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699855 on ClinicalTrials.gov